1. Benjamin EJ, Virani SS, Callaway CW, et al; on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2019 at-a-glance. Accessed January 10, 2020.
  2. American Heart Association. Cardiovascular disease: a costly burden for America. Projections through 2035. Accessed January 10, 2020.
  3. American Heart Association. HDL (good), LDL (bad) cholesterol and triglycerides. Accessed January 10, 2020.
  4. Centers for Disease Control and Prevention. Women and heart disease. Accessed January 10, 2020.
  5. Centers for Disease Control and Prevention. Heart disease fact sheet. Accessed January 10, 2020.
  6. National Institutes of Health. Ischemic heart disease. health-topics/ischemic-heart-disease. Accessed January 10, 2020.
  7. Salami JA. Warriach H, Valero-Elizondo J, et al. National Trends in Statin Use and Expenditures in the US Adult Population From 2002 to 2013: Insights From the Medical Expenditure Panel Survey. JAMA Cardiol. 2017;2(1):56-65.
  8. Byrne P, Cullinan J, Smith A, Smith SM. Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews. [Epub ahead of print April 23, 2019]. BMJ Open. doi: 10.1136/bmjopen-2018-023085.
  9. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018;72(3):330-343.
  10. Borow KM, Nelson JR, Mason RP. Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis. 2015;242(1):357-366.
  11. What you need to know about dietary supplements. US Food and Drug Administration website. Updated November 2017. Accessed January 10, 2020.
  12. Department of Health and Human Services. [Docket no. FDA–2016–N–1127]: AbbVie Inc., et al; Withdrawal of approval of indications related to the coadministration with statins in applications for niacin extended-release tablets and fenofibric acid delayed-release capsules. Federal Register. April 18, 2016;81(74):22612-22613.
  13. Kolber MR, Nickonchuk T, Turgeon R. Do PCSK9 inhibitors reduce cardiovascular events? Can Fam Physician. 2018;64(9):669.
  14. Rosenson N, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. J Am Coll Cardiol. 2018;72(3):314-329.
  15. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. [Epub ahead of print January 31, 2013]. Chocrane Database Syst Rev. doi: 10.1002/14651858.CD004816.pub5
  16. Pharmacy Times. FDA approves first PCSK9 inhibitor. Published July 24, 2015. Accessed January 10, 2020.
  17. MedPage Today. Second PCSK9 inhibitor approved for CV prevention. Accessed January 10, 2020.
  18. McClellan M, Brown N, Califf RM, Warner JJ. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory from the American Heart Association. Circulation. 2019;139(9):e44-e54.
  19. Murphy SL, Xu J, Kochanek KD, Arias E. Mortality in the United States, 2017. NCHS Data Brief. 2018;(328):1-8.
  20. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. Lancet. 2010;376(9748):1261-1271.
  21. Our World in Data. Does the news reflect what we die from? Published May 29, 2019. Accessed January 10, 2020.
  22. American Heart Association. Understand your risks to prevent a heart attack. Accessed January 10, 2020.
  23. National Institutes of Health. Atherosclerosis. Accessed January 10, 2020.
  24. Furie MB, Mitchell RN. Plaque attack: one hundred years of atherosclerosis in The American Journal of Pathology. Am J Pathol. 2012;180(6):2184-2187.
  25. Insull W JR. The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. Am J Med. 2009;122(1 Suppl):S3-S14.
  26. National Institutes of Health. Heart attack. Accessed January 10, 2020.
  27. National Institutes of Health. Stroke. Accessed January 10, 2020.
  28. American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical Care in diabetes—2019. Diabetes Care. 2019;42(suppl 1):S103-S123.
  29. National Institutes of Health. Omega-3 fatty acids. Updated October 17, 2019. Accessed January 10, 2020.
  30. Goel A, Pothineni NV, Singhal M, Paydak H, Saldeen T, Mehta JL. Fish, Fish Oils and Cardioprotection: Promise or Fish Tale? Int J Mol Sci. 2018;19(12):1-13.
  31. Aung T, Halsey J, Kromhout D, et al. Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals. JAMA Cardiol. 2018;3(3):225-234.
  32. Sherratt SCR, Mason Rp. Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid. Biochem Biophys Res Commun. 2018;496(2):335-338.
  33. Hilleman D, Smer A. Prescription omega-3 fatty acid products and dietary supplements are not interchangeable. Manag Care. 2016;25(1):46-52.
  34. Davidson MH. Omega-3 fatty acids: new insights into the pharmacology and biology of docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid. Curr Opin Lipidol. 2013;24(6):467-474.
  35. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. [Epub ahead of print November 3, 2011]. J Clin Lipidol. doi: 10.1016/j.jacl.2011.10.018.